Mobocertinib

Takeda will work with the FDA toward voluntary withdrawal of its lung cancer therapy mobocertinib from the U.S. market, according to a company press release.

The FDA approved mobocertinib for treatment of certain patients with non-small cell lung cancer.

The FDA granted priority review to mobocertinib for treatment of certain patients with non-small cell lung cancer, according to the agent’s manufacturer.

The FDA granted breakthrough therapy designation to mobocertinib for treatment of certain patients with metastatic non-small cell lung cancer.